- NASDAQ:ATNX fell a further 1.47% on Tuesday as the markets pulled back from Monday’s rally.
- Athenex received a dreaded FDA letter asking for further clinical trial evidence.
- Following the report on Monday, Athenex dropped by 51% during the trading session.
NASDAQ:ATNX is showing just how risky clinical stage biotech companies can be as an investment when much of the firm’s focus lies in one treatment. On Tuesday, shares of Athenex extended their losses and shed 1.47% as the broader markets retreated from the rebound to start the week on Monday. Athenex saw ten times the average trading volume on Tuesday as investors continued to sell off after the stock hit a new 52-week low price of $5.24 on Monday.
Stay up to speed with hot stocks' news!
The catalyst for Athenex’s freefall is of course the dreaded FDA letter that companies receive when applying for regulatory approval of its NDA or New Drug Application. The FDA rejected Athenex’s breast cancer treatment based on the recent clinical trial results, and recommended that Athenex start a brand new clinical trial before applying again. The letter outlines concerns that the FDA had in relation to patient safety regarding the oral medication in comparison to its IV treatment. The FDA also had concerns with Athenex’s trials not being representative of metastatic breast cancer patients in the United States, which may mean Athenex will need to shift its focus to a stateside trial. Athenex has said they will be scheduling a meeting with the FDA to figure out a response and next steps for a new clinical trial.
ATNX stock forecast
Not surprisingly, Athenex dropped 51% on Monday after the report of the letter, which also coincided with its quarterly earnings call. The news prompted some analyst downgrades of Athenex, including one from Truist Securities which downgraded ATNX from a buy to a hold. It should be noted that the FDA has not rejected the treatment forever, so if Athenex is able to put together a successful clinical trial, the current price levels could be seen as a value play.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds above 1.0700 after German inflation data
EUR/USD trades modestly higher on the day above 1.0700. The data from Germany showed that the annual HICP inflation edged higher to 2.4% in April. This reading came in above the market expectation of 2.3% and helped the Euro hold its ground.
USD/JPY recovers above 156.00 following suspected intervention
USD/JPY recovers ground and trades above 156.00 after sliding to 154.50 on what seemed like a Japanese FX intervention. Later this week, Federal Reserve's policy decisions and US employment data could trigger the next big action.
Gold holds steady above $2,330 to start the week
Gold fluctuates in a relatively tight channel above $2,330 on Monday. The benchmark 10-year US Treasury bond yield corrects lower and helps XAU/USD limit its losses ahead of this week's key Fed policy meeting.
Week Ahead: Bitcoin could surprise investors this week Premium
Two main macroeconomic events this week could attempt to sway the crypto markets. Bitcoin (BTC), which showed strength last week, has slipped into a short-term consolidation.
Five Fundamentals for the week: Fed fears, Nonfarm Payrolls, Middle East promise an explosive week Premium
Higher inflation is set to push Fed Chair Powell and his colleagues to a hawkish decision. Nonfarm Payrolls are set to rock markets, but the ISM Services PMI released immediately afterward could steal the show.